Investments by any U.S. MMF
https://www.financialresearch.gov/money-market-funds/
글
Changes in Net Worth: Households and Nonprofit Organizations
https://www.federalreserve.gov/releases/z1/dataviz/z1/changes_in_net_worth/chart/
NBTS , NBIS , CRWV
```html NVTS, NBIS, CRWV 재무 분석 NVTS, NBIS, CRWV 재무 분석 비교 아래는 Navitas Semiconductor (NVTS), Nebius Group (NBIS), CoreWeave (CRWV)의 대차대조표, 손익계산서, 가중평균자본비용(WACC)을 비교한 분석입니다. 데이터는 웹에서 수집된 정보를 기반으로 하며, NBIS의 경우 데이터가 제한적입니다. 1. 대차대조표 비교 Navitas Semiconductor (NVTS) 자산 : 총 자산 약 3억~4억 달러. 현금 1억~1.5억 달러, 무형자산(특허) 및 제조 설비 중심. 부채 : 단기 부채 3천만~6천만 달러, 장기 부채 적음. 부채비율 낮음. 자본 : 주주 자본 2억 달러 이상, 공모 자금 중심. Nebius Group (NBIS) 자산 : 총 자산 7억~10억 달러. 현금 2억~5억 달러, 소프트웨어/지적재산권 중심. 부채 : 단기 부채 5천만~1억 달러, 부채비율 0.2~0.5. 자본 : 주주 자본 5억~10억 달러, 공모/사모 자금. CoreWeave (CRWV) 자산 : 총 자산 10억 달러 이상. 데이터센터/GPU 등 고정자산 5억~10억 달러, 현금 1억~3억 달러. 부채 : 장기 부채 5억 달러 이상, 단기 부채 1억~2억 달러. 자본 : 주주 자본 5억~10억 달러, 벤처/상장 자금. 비교 자산 규모 : CRWV > NBIS > NV...
Why REGN Stock Has Been Down Recently
Regeneron Stock Analysis and Pharmaceutical Strategies Regeneron Stock Analysis and Pharmaceutical Strategies Why REGN Stock Has Been Down Recently Regeneron Pharmaceuticals (REGN) stock has experienced a significant decline recently, primarily due to several key setbacks that have impacted investor confidence. The following factors explain the downturn: Failure of Itepekimab in Phase 3 Clinical Trial : On May 30, 2025, REGN stock crashed approximately 19% after the company announced that its experimental chronic obstructive pulmonary disease (COPD) treatment, itepekimab (developed in partnership with Sanofi), failed to meet its primary endpoint in one of two Phase 3 clinical trials. This was a significant blow, as itepekimab was projected to be a blockbuster drug with potential peak sales of $2 billion to $6 billion. The failure likely delays regulatory approval and has raised concerns about the drug’s future viability. ...